The physiology of glucagon-like peptide 1.

By Jens J. Holst. Physiological Reviews, 2007

3,254 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/344c7523b0b051bf4c6fed4e7bcd69a8e19a4c23

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Josephine M. Egan
2. Wook Kim
3. M. Nauck
4. D. J. Drucker
5. F. Reimann
6. F. Gribble
7. Ralph DeFronzo
8. J. Meier

In Molecular Biology

1. M. Nauck
2. Josephine M. Egan
3. Wook Kim
4. D. J. Drucker

In Surgery

1. M. Nauck
2. Josephine M. Egan
3. Wook Kim
4. D. J. Drucker
5. F. Reimann
6. F. Gribble
7. Ralph DeFronzo
8. J. Meier

Citations in the corpus

• Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2 (2012, background): “L cells are a component of the enteroendocrine system, diffusely located along the length of the intestinal epithelium (5).”
• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024, background): “178,179 Additionally, cAMP can activate Rap1 through EPAC (Exchange Protein directly Activated by cAMP), 180 – 182 which is involved in regulating insulin secretion.”
• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “Both somatostatin antibodies and somatostatin receptor 2 antagonists abolished the GLP-1-induced inhibition of glucagon secretion in the perfused rat pancreas (Holst, 2007), leading to the conclusion that GLP-1 treatment, by inducing somatostatin secretion, suppresses glucagon secretion.”
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes (2008, neutral): “Noncompliance 2 (1) 4 (2) 4 (2) 5 (2) 4 (3)”
• Na+-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion (2011, background): “Active forms of GLP-1 and GIP are detectable in the systemic blood of human subjects after glucose ingestion (38,39), but are rapidly inactivated in the circulation by DPP-IV (10).”
• The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. (2014, positive): “Physiologically, GLP-1 released from endocrine cells lining the gut acts peripherally (13, 42).”
• Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. (2008, neutral): “restored under normal glycemic conditions (18).”
• Glucagon-like peptide 1 (GLP-1) (2019, background): “Consequently, as discussed in a comprehensive review [152], a large portion of intestinal GLP-1 is already degraded in the capillaries of the distal gut with an estimatedw25% of active GLP-1 reaching the liver and only w10e15% reaching the general circulation [152,176,183,191].”
• Glucose Sensing in L Cells: A Primary Cell Study (2008, background): “GLP-1 mimetics and inhibitors of GLP-1 degradation are already licensed for the treatment of type 2 diabetes, exploiting the important role of GLP-1 in the stimulation and maintenance of insulin release from pancreatic β cells and in the control of appetite (Drucker and Nauck, 2006; Holst, 2007).”
• Homeostasis, Inflammation, and Disease Susceptibility (2015, neutral): “For example, the gut hormone, GLP-1, reports on dietary glucose inflow, and therefore anticipates rising systemic glucose stock (which is itself reported by insulin) (Holst, 2007).”